Dendreon Scouts for Next Manufacturing Plant, Probably Far From Salmon and Evergreens
Summary
The company already has its first manufacturing plant for sipuleucel-T (Provenge) in Morris Plains, NJ, which, not coincidentally, is smack in the middle of the biggest concentration of prostate cancer patients in the U.S., according to this slide that Dendreon prepared for its investors several years ago.Because of the nature of Dendreon’s manufacturing process, in which it is important to be close to patients, then it almost has to look in the southeastern U.S., based on this company-produced map, and this report on geographic distribution of prostate cancer incidence in the U.S. created by the Centers for Disease Control and Prevention.The Dendreon map in particular, as you can see, shows a tight concentration of prostate cancer drug sales in the New York/New Jersey corridor, the retirement communities of south Florida, and in the Upper Midwest population centers of greater Chicago and Detroit.Inside that geographic triangle in the east, you have one of the world’s busiest airports at Atlanta’s Hartsfield International, and you have Memphis, TN, home of FedEx.The company raised $221 million from investors after it presented clinical trial results in April showing Provenge helped men with terminal prostate cancer live longer.
Classifications
AskAI Classifications
LabelsLinked Companies
